Plos Med:坚持健康的生活方式,可极大降低结直肠癌患病风险

2021-02-20 MedSci原创 MedSci原创

据数据显示,结直肠癌(CRC)是美国第三大最常被诊断的癌症和第三大癌症死亡原因。既往研究显示,坚持健康的生活方式可预防20%到70%的CRC死亡率。然而,健康生活方式很难长期坚持,特别是对于内窥镜检查

据数据显示,结直肠癌CRC)是美国第三大最常被诊断的癌症和第三大癌症死亡原因。既往研究显示,坚持健康的生活方式可预防20%70%CRC死亡率。然而,健康生活方式很难长期坚持,特别是对于内窥镜检查筛查呈现阴性的人群。那么,对于已经接受过内镜筛查的人群来说,健康的生活方式是否与没有接受内镜筛查的人群一样,目前还不得而知。与单纯的内镜筛查相比,将健康的生活方式与内镜筛查结合起来是否可以预防CRC的也是未知的。

近日,发表在Plos Med杂志的一项研究,在两个大型的前瞻性队列研究中,无论是否进行内窥镜筛查,坚持健康的生活方式可降低CRC发生率和死亡率。仅通过内窥镜筛查就能预防大约32%的CRC发病率和34CRC死亡率,而与健康的生活方式相结合,预防CRC发病率和死亡率的比率分别增加到61%和55%,对近端结肠癌尤为明显。

在这项研究中,研究人员对美国两个大型队列研究,护士健康研究(NHS)和卫生专业人员随访研究(HPFS)进行健康生活方式与接受/未接受内镜筛查对CRC发病率和死亡率影响的评估。其中,包含75873名女性和42875名男性,平均年龄为54岁。研究人员根据体重指数、吸烟、体力活动、饮酒和饮食来定义健康生活方式评分,进而评估CRC发病率和死亡率与健康生活方式评分相关的危险比(HRs)和人群归因危险度(PAR)

结果显示,随访26年后,共记录了2836CRC病例和1013CRC死亡病例。无论是否进行内镜检查,健康的生活方式评分与较低的CRC发生率存在关联。单纯通过内镜筛查可能预防的CRC病例的比率(PAR)为32%95% CI31%33%),与健康生活方式相结合时(得分=5),增加到61%95% CI42%75%)。对于近端结肠癌,相应的PAR15%13%16%)增加到51%17%74%),对于远端结肠癌,从47%45%50%)增加到75%61%84%)。CRC死亡率的结果相似。

健康生活方式评分与CRC发病率(A组)和死亡率(B组)的关系,以及相应的年龄调整后的发病率和死亡率

与内窥镜筛查和健康生活方式相关的CRC发病率和死亡率

总而言之,该研究结果为加强预防结直肠癌的公共卫生措施提供了有力的证据, 健康的生活方式与较低的CRC发生率和死亡率相关,而与内窥镜检查无关。与单纯的内窥镜检查相比,将健康的生活方式与内窥镜检查相结合可以显著增强对CRC的预防,特别是对近端结肠癌的预防。

原始出处

Kai Wang.et al.Healthy lifestyle, endoscopic screening, and colorectal cancer incidence and mortality in the United States: A nationwide cohort study. Plos Med.https://doi.org/10.1371/journal.pmed.1003522

版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1281788, encodeId=40f51281e882a, content=<a href='/topic/show?id=ef315299070' target=_blank style='color:#2F92EE;'>#患病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52990, encryptionId=ef315299070, topicName=患病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Mon Feb 22 13:23:19 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453479, encodeId=594d14534e930, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Mon Feb 22 13:23:19 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610907, encodeId=683f161090ee0, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Feb 22 13:23:19 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926251, encodeId=770892625124, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sun Feb 21 23:12:23 CST 2021, time=2021-02-21, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1281788, encodeId=40f51281e882a, content=<a href='/topic/show?id=ef315299070' target=_blank style='color:#2F92EE;'>#患病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52990, encryptionId=ef315299070, topicName=患病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Mon Feb 22 13:23:19 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453479, encodeId=594d14534e930, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Mon Feb 22 13:23:19 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610907, encodeId=683f161090ee0, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Feb 22 13:23:19 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926251, encodeId=770892625124, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sun Feb 21 23:12:23 CST 2021, time=2021-02-21, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1281788, encodeId=40f51281e882a, content=<a href='/topic/show?id=ef315299070' target=_blank style='color:#2F92EE;'>#患病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52990, encryptionId=ef315299070, topicName=患病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Mon Feb 22 13:23:19 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453479, encodeId=594d14534e930, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Mon Feb 22 13:23:19 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610907, encodeId=683f161090ee0, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Feb 22 13:23:19 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926251, encodeId=770892625124, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sun Feb 21 23:12:23 CST 2021, time=2021-02-21, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1281788, encodeId=40f51281e882a, content=<a href='/topic/show?id=ef315299070' target=_blank style='color:#2F92EE;'>#患病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52990, encryptionId=ef315299070, topicName=患病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Mon Feb 22 13:23:19 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453479, encodeId=594d14534e930, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Mon Feb 22 13:23:19 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610907, encodeId=683f161090ee0, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Feb 22 13:23:19 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926251, encodeId=770892625124, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sun Feb 21 23:12:23 CST 2021, time=2021-02-21, status=1, ipAttribution=)]
    2021-02-21 1209e435m98(暂无昵称)

    学习了,谢谢分享

    0

相关威廉亚洲官网

J Natl Cancer Inst:阿司匹林怎么吃、什么时候开始吃、吃多久可预防结直肠癌?

阿司匹林可预防结直肠癌,该怎么吃、什么时候开始吃、吃多久呢?

Cell Death Differ:PARP1、MRE11和RAD51共同影响结直肠癌肿瘤干细胞的DNA复制应激和有丝分裂

包括结直肠癌(CRC)在内的大多数人实体瘤表现出了在基因、表观遗传、转录和/或表型水平上的患者之间以及肿瘤内的较大的异质性,这也是癌症治疗和患者生存的主要障碍。

JAMA Netw Open:摄入较高的膳食纤维,钙和酸奶可降低结直肠癌发病率

在世界范围内,结直肠癌(CRC)是男性中第三大最常被诊断出的癌症,也是女性第二大最常被诊断出的癌症。CRC的病因是多因素的,其中,遗传因素和环境因素起主要作用。

J Natl Cancer Inst:确诊结直肠癌后再吃阿司匹林是否还能降低患者的死亡风险?

确诊CRC后再服用阿司匹林是否还能获得生存益处?

结直肠癌候选药物RCC-33将小鼠肿瘤体积降低了27%

中期结果显示,与对照小鼠相比,暴露于RCC-33的小鼠的肿瘤体积减少了27%。